Citations

Objective: To report a case in which a young woman receiving medroxyprogesterone acetate injections developed deep vein thrombosis (DVT) after prolonged travel. Case Summary: An obese 27-year-old African American woman who had been receiving medroxyprogesterone acetate injections 150 mg intramuscularly every 3 months for 6 years experienced DVT after a 56-hour car ride. The patient's known risk factors for DVT included immobility, obesity (140 kg), and medroxyprogesterone acetate therapy. Family and personal history for thrombotic events were denied. Tests were performed after detection of the DVT to assess the patient for anticoagulation defects; results revealed an unidentified underlying protein S deficiency. All other test results were within normal limits. Discussion: Based on the Naranjo probability scale, it is possible that the DVT experienced by our patient was due to medroxyprogesterone acetate. Although she did have other risk factors for DVT, her underlying protein S deficiency was diagnosed after the thrombosis. Literature describing the relationship between the injectable form of contraception and thrombosis is limited. Therefore, this report reviews protein S deficiency, the relationship between oral contraceptives (OCs) and thrombosis, the influence of immobility on thrombosis development, and the clinical implications of evaluating patients for underlying inherited clotting abnormalities before initiating OCs. Conclusions: When considering whether to prescribe contraceptives, clinicians should assess the patient's risk factors for thrombosis, such as family or personal history. Although generally not recommended, prescreening tests may be considered if there is a positive family or personal history.

Objective— Endothelial outgrowth cells (EOC) decrease inflammation and improve endothelial repair. Inflammation aggravates kidney injury in renal artery stenosis (RAS), and may account for its persistence upon revascularization. We hypothesized that EOC would decrease inflammatory (M1) macrophages and improve renal recovery in RAS. Approach and Results— Pigs with 10 weeks of RAS were studied 4 weeks after percutaneous transluminal renal angioplasty (PTRA+stenting) or sham, with or without adjunct intrarenal delivery of autologous EOC (10×10 6 ), and compared with similarly treated normal controls (n=7 each). Single-kidney function, microvascular and tissue remodeling, inflammation, oxidative stress, and fibrosis were evaluated. Four weeks after PTRA, EOC were engrafted in injected RAS-kidneys. Stenotic-kidney glomerular filtration rate was restored in RAS+EOC, RAS+PTRA, and RAS+PTRA+EOC pigs, whereas stenotic-kidney blood flow and angiogenesis were improved and fibrosis attenuated only in EOC-treated pigs. Furthermore, EOC increased cell proliferation and decreased the ratio of M1 (inflammatory)/M2 (reparative) macrophages, as well as circulating levels and stenotic-kidney release of inflammatory cytokines. Cultured-EOC released microvesicles in vitro and induced phenotypic switch (M1-to-M2) in cultured monocytes, which was inhibited by vascular endothelial growth factor blockade. Finally, a single intrarenal injection of rh-vascular endothelial growth factor (0.05 μg/kg) in 7 additional RAS pigs also restored M1/M2 ratio 4 weeks later. Conclusions— Intrarenal infusion of EOC after PTRA induced a vascular endothelial growth factor–mediated attenuation in macrophages inflammatory phenotype, preserved microvascular architecture and function, and decreased inflammation and fibrosis in the stenotic kidney, suggesting a novel mechanism and therapeutic potential for adjunctive EOC delivery in experimental RAS to improve PTRA outcomes.

Purpose The purpose of this study was to evaluate whether transporting insulin aspart FlexPens via a pneumatic tube system affects the dosing accuracy of the pens. Methods A total of 115 Novo Nordisk FlexPens containing insulin aspart were randomly assigned to be transported via a pneumatic tube system (n = 92) or to serve as the control (n = 23). Each pen was then randomized to 10 international unit (IU) doses (n = 25) or 30 IU doses (n = 67), providing 600 and 603 doses, respectively, for the pneumatic tube group. The control group also received random assignment to 10 IU doses (n = 6) or 30 IU doses (n = 17), providing 144 and 153 doses, respectively. Each dose was expelled using manufacturer instructions. Weights were recorded, corrected for specific gravity, and evaluated based on acceptable International Organization for Standardization (ISO) dosing limits. Results In the group of pens transported through the pneumatic tube system, none of the 600 doses of 10 IU (0.0%; 95% CI, 0.0 to 0.6) and none of the 603 doses of 30 IU (0.0%; 95% CI, 0.0 to 0.6) fell outside of the range of acceptable weights. Correspondingly, in the control group, none of the 144 doses at 10 IU (0.0%; 95% CI, 0.0 to 2.5) and none of the 153 doses at 30 IU (0.0%; 95% CI, 0.0 to 2.4) were outside of acceptable ISO limits. Conclusion Transportation via pneumatic tube system does not appear to compromise dosing accuracy. Hospital pharmacies may rely on the pneumatic tube system for timely and accurate transport of insulin aspart FlexPens.

Polycystic kidney (PKD) and liver (PLD) diseases cause significant morbidity and mortality. A large body of evidence indicates that cyclic AMP plays an important role in their pathogenesis. Clinical trials of drugs that reduce cyclic AMP levels in target tissues are now in progress. Secretin may contribute to adenylyl cyclase-dependent urinary concentration and is a major agonist of adenylyl cyclase in cholangiocytes. To investigate the role of secretin in PKD and PLD, we have studied the expression of secretin and the secretin receptor in rodent models orthologous to autosomal recessive ( PCK rat) and dominant ( Pkd2−/WS25mouse) PKD; the effects of exogenous secretin administration to PCK rats, PCK rats lacking circulating vasopressin ( PCKdi/di), and Pkd2−/WS25mice; and the impact of a nonfunctional secretin receptor on disease development in Pkd2−/WS25:SCTR−/−double mutants. Renal and hepatic secretin and secretin receptor mRNA and plasma secretin were increased in both models, and secretin receptor protein was increased in the kidneys and liver of Pkd2−/WS25mice. However, exogenous secretin administered subcutaneously via osmotic pumps had minimal or negligible effects and the absence of a functional secretin receptor had no influence on the severity of PKD or PLD. Therefore, it is unlikely that by itself secretin plays a significant role in the pathogenesis of PKD and/or PLD.

Abstract Background: Ingested nitrate can form N-nitroso compounds endogenously, which may lead to DNA adducts and activating mutations in oncogenes. However, previous studies have reported null or inverse associations between dietary nitrate intake and cancer risk, while nitrate intake from drinking water has shown null or positive associations with cancer risk. These associations may be confounded by protective effects of dietary folate, which provides methyl groups for nucleotide synthesis, and thus plays a vital role in the DNA repair system. In a small case-control study, an increased risk of breast cancer was observed among individuals with high dietary nitrate relative to folate intake. We therefore evaluated interaction of total folate with nitrate intake from diet and drinking water on breast cancer risk in the Iowa Women's Health Study (IWHS). Methods: The IWHS is a prospective cohort study of cancer among 41,836 women in Iowa, initiated in 1986. Dietary intake was assessed at study baseline using a food frequency questionnaire (FFQ). Nitrate intake from foods and total folate intake from foods and dietary supplements were computed using consumption frequencies collected by the FFQ. Nitrate intake from drinking water was assessed using a historical analytical database on Iowa municipal water supplies in 15,151 women using municipal water supply. We evaluated the interaction of nitrate and total folate intake with breast cancer risk using Cox proportional hazard regression modeling, adjusting for potential confounders (age, body mass index, waist-hip-ratio, education, smoking, family history of breast cancer, age at menopause, age at first live birth, estrogen use, total energy intake, and intake of vitamin C and E and flavonoids). Results: After baseline exclusions (history of cancer at baseline, previous mastectomy or partial breast resection, implausible energy intake, or ≥30 missing responses on the FFQ), there were 34,388 postmenopausal women in the analytic cohort. Through 2008, 2,875 incident breast cancer cases were identified. Nitrate intake from diet or drinking water was not associated with breast cancer risk. After stratification by total folate intake, high dietary nitrate intake (>106.1 mg/day) was associated with a marginally decreased risk of breast cancer compared to those with low nitrate intake (≤106.1 mg/day) (HR=0.90, 95% confidence interval=0.81–1.00) only among women with folate intake <400 μg/day (p for interaction = 0.65). There was no interaction of nitrate intake from drinking water and total folate intake on breast cancer risk. Conclusions: Our findings do not support the previously reported increased risk of breast cancer risk among individuals with high dietary nitrate and low folate intake. The inverse association between nitrate intake and breast cancer risk observed among women with low folate intake in the present study may be attributed to residual confounding due to high correlation among intakes of nitrate, folate and antioxidants. Citation Information: Cancer Prev Res 2011;4(10 Suppl):A86.